Anti-Inflammatory drug may boost chemo for aggressive lymphoma

NCT ID NCT07494565

Recruiting now Disease control Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 23, 2026 · Updated 3 times

Summary

This phase 2 trial tests whether adding the anti-inflammatory drug celecoxib to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed, advanced CD5-positive diffuse large B-cell lymphoma (a fast-growing type). Sixty participants will be randomly assigned to receive either celecoxib plus R-CHOP or R-CHOP alone. The main goal is to see if the combination leads to more complete remissions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Celecoxib (an anti-inflammatory drug) combined with R-CHOP chemotherapy
What this could lead to: If it works, this could improve the chance of complete remission for people with a hard-to-treat type of lymphoma.
What could go wrong: This is a small, early-phase trial (60 people) and may not show a clear benefit. Adding celecoxib could also increase side effects like stomach or heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD5 POSITIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD5 POSITIVE DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL)

Contacts and locations

Locations

Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.